Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ricardo Estupinian"'
Autor:
Ruchi Roy, Janet Zayas, Sunil K Singh, Kaylee Delgado, Stephen J Wood, Mohamed F Mohamed, Dulce M Frausto, Yasmeen A Albalawi, Thea P Price, Ricardo Estupinian, Eileena F Giurini, Timothy M Kuzel, Andrew Zloza, Jochen Reiser, Sasha H Shafikhani
Publikováno v:
eLife, Vol 11 (2022)
Infection is a major co-morbidity that contributes to impaired healing in diabetic wounds. Although impairments in diabetic neutrophils have been blamed for this co-morbidity, what causes these impairments and whether they can be overcome, remain lar
Externí odkaz:
https://doaj.org/article/1c02e2dfb8ec424ab1fb84f3147a9313
Autor:
Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson, Evita T. Sadimin, Shengguo Li, Daniel J. Medina, Tracie Saunders, Melissa Frankel, Aparna Kareddula, Sherrie Damare, Elayne Wesolowsky, Christian Gabel, Wafik S. El-Deiry, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Joseph R. Bertino, Steven K. Libutti, Janice M. Mehnert, Andrew Zloza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human tri
Externí odkaz:
https://doaj.org/article/cc2e3e6b70b34104941a2588a1bfa557
Autor:
Janet Zayas, Ruchi Roy, Sunil K Singh, Kaylee Delgado, Stephen J Wood, Mohamed F Mohamed, Dulce M Frausto, Yasmeen A Albalawi, Thea P Price, Ricardo Estupinian, Eileena F Giurini, Timothy M Kuzel, Andrew Zloza, Jochen Reiser, Sasha H Shafikhani
Publikováno v:
eLife, Vol 11 (2022)
Infection is a major co-morbidity that contributes to impaired healing in diabetic wounds. Although impairments in diabetic neutrophils have been blamed for this co-morbidity, what causes these impairments and whether they can be overcome, remain lar
Autor:
Joseph R. Broucek, Eileena F. Giurini, Nora L. Herzog, Lisa K. Denzin, Gabriel Guevara-Aleman, C. Brent Chesson, Ricardo Estupinian, Marco Rossi, Mary J. Fidler, Raquel E. Redondo, Jai S. Rudra, Joyce Paras, Jochen Reiser, Amanda L. Marzo, Jyoti Malhotra, Shang Jui Wang, Emily S. Ruiz, Stuti Buddhadev, Howard L. Kaufman, Saeed Tarabichi, Sachin R. Jhawar, Frederick J. Kohlhapp, Daniel J. Medina, Mones M. Aboelatta, David Rotter, Shengguo Li, Leonard Y. Lee, Vineet Gupta, John Langenfeld, Ann W. Silk, Russell J. Pepe, Kajal Gupta, Timothy M. Kuzel, Jason M. Schenkel, Derek B. Sant'Angelo, Abdulkareem Abed, Jenna H. Newman, Michael J. Lee, Praveen K. Bommareddy, Salvatore M. Aspromonte, Ahmed Lasfar, Eric A. Singer, Michael P. Kane, Christina Nowicki, Arnold B. Rabson, Andrew Zloza, Paul G. Thomas, Josef W. Goldufsky
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Immunotherapy has revolutionized cancer treatment, yielding unprecedented long-term responses and survival. However, a significant proportion of patients remain refractory, which correlates with the absence of immune-infiltrated (“hot
Autor:
Janet Zayas, Ruchi Roy, Sunil K Singh, Kaylee Delgado, Stephen J Wood, Mohamed F Mohamed, Dulce M Frausto, Yasmeen A Albalawi, Thea P Price, Ricardo Estupinian, Eileena F Giurini, Timothy M Kuzel, Andrew Zloza, Jochen Reiser, Sasha H Shafikhani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::715ecd28aea77c11b7e5c279e412acae
https://doi.org/10.7554/elife.72071.sa2
https://doi.org/10.7554/elife.72071.sa2
Autor:
Jochen Reiser, Ruchi Roy, Janet Zayas, Timothy M. Kuzel, Sasha H. Shafikhani, Dulce M. Frausto, Mohamed F. Mohamed, Stephen Wood, Ricardo Estupinian, Eileena F. Giurini, Andrew Zloza
Infection is a major co-morbidity that contributes to impaired healing in diabetic wounds. Although impairments in diabetic neutrophils have been blamed for this co-morbidity, what causes these impairments and whether they can be overcome, remain lar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10687e3bf305f2d56bea57f78c99542b
https://doi.org/10.1101/2021.09.09.459638
https://doi.org/10.1101/2021.09.09.459638
Autor:
Ajeet Gajra, Ricardo Estupinian, Stephanie Fortier, Yolaine Jeune-Smith, Bruce A. Feinberg, Ulka N. Vaishampayan
Publikováno v:
Journal of Clinical Oncology. 40:120-120
120 Background: Metastatic castration-resistant prostate cancer (mCRPC) is a difficult-to-treat cancer with poor patient outcomes. In June 2021, 177Lu-PSMA-617 was granted U.S. FDA breakthrough designation for the treatment of mCRPC based on results
Autor:
Praveen K. Bommareddy, Wafik S. El-Deiry, Tracie Saunders, Salvatore M. Aspromonte, Lorna Rodriguez, Rohinton Tarapore, Janice M. Mehnert, Steven K. Libutti, Nancy Chan, Ann W. Silk, Jenna H. Newman, Charles B. Chesson, Elayne Wesolowsky, Daniel J. Medina, Christian Gabel, Martin Stogniew, Shengguo Li, Joseph R. Bertino, Joshua E. Allen, Mark N. Stein, Evita Sadimin, Aparna Kareddula, Joseph Aisner, Sherrie Damare, Jyoti Malhotra, Wolfgang Oster, Varun V. Prabhu, Bruce G. Haffty, Andrew Zloza, Ricardo Estupinian, Tina M. Mayer, Melissa Frankel, Robert Aiken, Usha Malhotra
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Background ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human trial of ONC
Autor:
Jenna H Newman, Brent Chesson, Nora Herzog, Praveen Bommareddy, Salvatore Aspromonte, Russell Pepe, Ricardo Estupinian, Mones Aboelatta, Stuti Buddhadev, Jason Schenkel, Paul Thomas, Jai Rudra, Ann Silk, Andrew Zloza
Publikováno v:
The Journal of Immunology. 202:136.6-136.6
Immunotherapy has revolutionized cancer treatment; however, a significant fraction of patients exhibit resistance to immunotherapy, in part due to the lack of an inflamed (“hot”) tumor microenvironment. Seeking to recruit immune cells to tumors l
Autor:
Jenna H. Newman, Charles Brent Chesson, Salvatore Aspromonte, Praveen K. Bommareddy, Russell Pepe, Saeed Tarabichi, Shengguo Li, Sachin Jhawar, Nora L. Herzog, Mones Aboelatta, Eshan Kaul, Ricardo Estupinian, Michael P. Kane, Ann Silk, Andrew Zloza
Publikováno v:
The Journal of Immunology. 200:178.44-178.44
In recent years, immunotherapy has yielded increased survival for cancer patients; however, a significant percentage of patient tumors remain refractory to immunotherapy. This is due in part to the absence of an inflamed tumor microenvironment. In ou